These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 9267788)
1. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Andriole GL Eur Urol; 1997; 32 Suppl 3():65-9. PubMed ID: 9267788 [TBL] [Abstract][Full Text] [Related]
2. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. Zincke H; Lau W; Bergstralh E; Blute ML J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737 [TBL] [Abstract][Full Text] [Related]
3. Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications. Han M; Pound CR; Potter SR; Partin AW; Epstein JI; Walsh PC J Urol; 2001 Mar; 165(3):864-6. PubMed ID: 11176487 [TBL] [Abstract][Full Text] [Related]
4. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related]
5. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793 [TBL] [Abstract][Full Text] [Related]
6. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. Wieder JA; Soloway MS J Urol; 1998 Aug; 160(2):299-315. PubMed ID: 9679867 [TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results. Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y; Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545 [TBL] [Abstract][Full Text] [Related]
8. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy. Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480 [TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy. Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941 [TBL] [Abstract][Full Text] [Related]
10. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Do T; Parker RG; Do C; Tran L; Do L; Dolkar D Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297 [TBL] [Abstract][Full Text] [Related]
11. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC; J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735 [TBL] [Abstract][Full Text] [Related]
13. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? King CR; Presti JC; Gill H; Brooks J; Hancock SL Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146 [TBL] [Abstract][Full Text] [Related]
14. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249 [TBL] [Abstract][Full Text] [Related]
15. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Simmons MN; Stephenson AJ; Klein EA Eur Urol; 2007 May; 51(5):1175-84. PubMed ID: 17240528 [TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer. Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667 [TBL] [Abstract][Full Text] [Related]
17. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984 [TBL] [Abstract][Full Text] [Related]
18. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435 [TBL] [Abstract][Full Text] [Related]
19. Combined androgen blockade: the gold standard for metastatic prostate cancer. McLeod DG; Crawford ED; DeAntoni EP Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789 [TBL] [Abstract][Full Text] [Related]
20. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis. Milecki P; Kwias Z; Martenka DJ Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]